Lisa Loksø Dietz

Lisa Loksø Dietz

Auto-generated profile, based on publicly available information

Lisa Loksø Dietz

Aarhus Univ, Dept Clin Med, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2023 in Communications Medicine
Verified
Journal Article
Open access
PDF file
LDLisa Loksø Dietz
Lisa Loksø Dietz
AJAnna Karina Juhl
Anna Karina Juhl
OSOle S. Søgaard
Ole S. Søgaard
JRJoanne Reekie
Joanne Reekie
HNHenrik Nielsen
Henrik Nielsen
MTMartin Tolstrup
Martin Tolstrup
Background: Older age and chronic disease are important risk factors for developing severe COVID-19. At population level, vaccine-induced immunity substantially reduces the risk of severe COVID-19 disease and hospitalization. However, the relative impact of humoral and cellular immunity on protection from breakthrough infection and severe disease is not fully understood. Methods: In a study cohort of 655 primarily older study participants (median of 63 years (IQR: 51–72)), we determined serum levels of Spike IgG antibodies using a Multiantigen Serological Assay and quantified the frequency of SARS-CoV-2 Spike-specific CD4 + and CD8 + T cells using activation induced marker assay. This enabled characterization of suboptimal vaccine-induced cellular immunity. The risk factors of being a cellular hypo responder were assessed using logistic regression. Further follow-up of study participants allowed for an evaluation of the impact of T cell immunity on breakthrough infections. Results: We show reduced serological immunity and frequency of CD4 + Spike-specific T cells in the oldest age group (≥75 years) and higher Charlson Comorbidity Index (CCI) categories. Male sex, age group ≥75 years, and CCI > 0 is associated with an increased likelihood of being a cellular hypo-responder while vaccine type is a significant risk factor. Assessing breakthrough infections, no protective effect of T cell immunity is identified. Conclusions: SARS-CoV-2 Spike-specific immune responses in both the cellular and serological compartment of the adaptive immune system increase with each vaccine dose and are progressively lower with older age and higher prevalence of comorbidities. The findings contribute to the understanding of the vaccine response in individuals with increased risk of severe COVID-19 disease and hospitalization.

30 April 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
AJAnna Karina Juhl
Anna Karina Juhl
LDLisa Loksø Dietz
Lisa Loksø Dietz
OSOle Schmeltz Søgaard
Ole Schmeltz Søgaard
JRJoanne Reekie
Joanne Reekie
HNHenrik Nielsen
Henrik Nielsen
MTMartin Tolstrup
Martin Tolstrup
Within a year of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, vaccines inducing a robust humoral and cellular immune response were implemented worldwide. However, emergence of novel variants and waning vaccine-induced immunity led to implementation of additional vaccine boosters. This prospective study evaluated the temporal profile of cellular and serological responses in a cohort of 639 SARS-CoV-2–vaccinated participants, of whom a large proportion experienced a SARS-CoV-2 infection. All participants were infection naïve at the time of their first vaccine dose. Proportions of SARS-CoV-2 spike–specific T cells were determined after each vaccine dose using the activation-induced marker assay, while levels of circulating SARS-CoV-2 antibodies were determined by the Meso Scale serology assay. We found a significant increase in SARS-CoV-2 spike–specific CD4+ and CD8+ T-cell responses following the third dose of a SARS-CoV-2 messenger RNA vaccine as well as enhanced CD8+ T-cell responses after the fourth dose. Furthermore, increased age was associated with a poorer response. Finally, we observed that SARS-CoV-2 infection boosts both the cellular and humoral immune response, relative to vaccine-induced immunity alone. Our findings highlight the boosting effect on T-cell immunity of repeated vaccine administration. The combination of multiple vaccine doses and SARS-CoV-2 infections maintains population T-cell immunity, although with reduced levels in the elderly. This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/longitudinal-evaluation-of-sars-cov-2-t-cell-immunity-over-2-years-following-vaccination-and-infection?utm_campaign=tidbitlinkshare&utm_source=ITP

3 March 2026 in Nature Immunology
Verified
Journal Article
Open access
KFKatie Fisher
Katie Fisher
MGMauro A. Garcia
Mauro A. Garcia
GFGiacomo S. Frattari
Giacomo S. Frattari
CNChloé Naasz
Chloé Naasz
JZJunlin Zhuo
Junlin Zhuo
OSOle S. Søgaard
Ole S. Søgaard
Antiretroviral therapy (ART) interruption typically leads to rapid HIV-1 viral rebound in people with HIV-1. To develop an HIV-1 cure, insight into immunological mechanisms capable of preventing HIV-1 viral rebound is urgently needed. Here, we describe three exceptional post-intervention controllers (PICs) who maintained ART-free virological control for >6.5 years (ongoing), >7.5 years (ongoing) and 2.5 years following administration of broadly neutralizing antibodies. PICs had quantifiable genetically intact/inducible infectious proviral reservoirs that were increasingly clonal and located in nongenic/centromeric chromosomal regions, indicating immune-mediated selection. Potent autologous neutralizing antibodies and polyfunctional HIV-1-specific CD4 + and CD8 + T cell responses, pre-programmed for antigen response, were present before, and persisted during, ART interruption. In one PIC, viral rebound following 2.5 years of ART-free control was associated with accumulated viral mutations that resulted in escape from neutralizing antibody and T cell responses. Collectively, our findings support developing HIV-1 curative strategies aimed at enhancing pre-existing adaptive immune responses.

25 May 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
JRJoanne Reekie
Joanne Reekie
HSHenrik Stovring
Henrik Stovring
HNHenrik Nielsen
Henrik Nielsen
IJIsik Somuncu Johansen
Isik Somuncu Johansen
TBThomas Benfield
Thomas Benfield
OSOle Schmeltz Søgaard
Ole Schmeltz Søgaard
Objectives: This study aimed to compare antibody trajectories among individuals with SARS-CoV-2 hybrid and vaccine-induced immunity. Methods: Danish adults receiving three doses of BTN162b2 or mRNA-1237 were included prior to first vaccination (Day 0). SARS-CoV-2 anti-spike IgG levels were assessed before each vaccine dose, at Day 90, Day 180, 28 days after 3rd vaccination (Day 251), Day 365, and prior to 4th vaccination (Day 535). SARS-CoV-2 PCR results were extracted from the national microbiology database. Mixed-effect multivariable linear regression investigated the impact of hybrid-immunity (stratified into 4 groups: no hybrid immunity, PCR+ prior to 3rd dose, PCR+ after 3rd dose and before Day 365, PCR+ after Day 365) on anti-spike IgG trajectories. Results: A total of 4,936 individuals were included, 47% developed hybrid-immunity. Anti-spike IgG increases were observed in all groups at Day 251, with the highest levels in those PCR+ prior to 3rd dose (Geometric Mean; 535,647AU/mL vs. 374,665AU/mL with no hybrid-immunity, P<0.0001). Further increases were observed in participants who developed hybrid immunity after their 3rd dose. Anti-spike IgG levels declined from Day 251-535 in individuals without hybrid-immunity and in those who developed hybrid-immunity prior to their 3rd dose, with lower rate of decline in those with hybrid-immunity. Conclusion: Hybrid-immunity results in higher and more durable antibody trajectories in vaccinated individuals. (c) 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

12 November 2019 in ADC Review / Journal of Antibody-drug Conjugates
Verified
Journal Article
Open access
HLHans-Georg Lerchen
Hans-Georg Lerchen
BSBeatrix M Stelte-Ludwig
Beatrix M Stelte-Ludwig
ASAnette Sommer
Anette Sommer
PAPharmaceuticals R&D Bayer Ag
Pharmaceuticals R&D Bayer Ag
DKDennis Kirchhoff
Dennis Kirchhoff
SJSandra Sandra Johanssen
Sandra Sandra Johanssen
With the approval of meanwhile five ADCs and more than 80 ADCs in clinical trials, the ADC landscape has developed rapidly during the last decade. However, as indicated also by the large number of ADCs which failed in the clinic, it remains challenging to achieve a sufficiently large therapeutic window in cancer patients. Furthermore, the identification of ADC payload classes with a novel mode of action would increase therapeutic options and potentially help to overcome resistance. Inhibitors of kinesin spindle protein (KSP/Eg5) have raised great interest because of their high antitumor potency which, however, could not be transferred into highly efficient clinical regimens due to dose limiting side effects such as neutropenia and mucositis.